Company Description
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 414 |
| CEO | Grant Pickering |
Contact Details
Address: 825 Industrial Road, Suite 300 San Carlos, California 94070 United States | |
| Phone | 650 837 0111 |
| Website | vaxcyte.com |
Stock Details
| Ticker Symbol | PCVX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001649094 |
| CUSIP Number | 92243G108 |
| ISIN Number | US92243G1085 |
| Employer ID | 46-4233385 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant E. Pickering M.B.A. | Co-Founder, Chief Executive Officer and Director |
| Andrew L. Guggenhime M.B.A. | President and Chief Financial Officer |
| James Wassil M.B.A., M.S. | Executive Vice President and Chief Operating Officer |
| Mikhail Eydelman J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| Dr. Jeff Fairman Ph.D. | Co-Founder and Vice President of Research |
| Janet Graesser | Senior Vice President of Corporate Communications and Investor Relations |
| Whitney Jones | Chief People Officer |
| Paul W. Sauer M.B.A. | Senior Vice President of Process Development and Manufacturing |
| Harp Dhaliwal M.B.A. | Chief Technical Operations Officer |
| Sam Iki | Senior Vice President of Project Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| May 7, 2025 | SCHEDULE 13G/A | Filing |
| May 1, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 31, 2025 | 8-K | Current Report |